Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...
Conditions: Echocardiography; Medical Student; Transthoracic Echocardiography; Education Intervention: Other: Basic cardiac ultrasound training with Butterfly iQ handheld ultrasound Sponsor: University of Hawaii Active, not recruiting
Conditions: Joint Diseases; Osteoarthritis, Hip; Rheumatoid Arthritis; Psoriatic Arthritis; Avascular Necrosis of Hip Intervention: Device: Routine Total Hip Arthroplasty Sponsor: Ortho Development Corporation Recruiting
Condition: Prostate Cancer Interventions: Biological: Denosumab; Drug: Enzalutamide; Drug: Abiraterone; Drug: Prednisone Sponsor: University of Hawaii Terminated
Conditions: Head Trauma; Cognitive Change; Confidence, Self; Sports Injuries in Children Interventions: Behavioral: HuTT-2x; Behavioral: HuTT-4x Sponsors: University of Massachusetts, Lowell; Gary O. Galiher Foundation; University of Hawaii; University of Michigan; Children's National Health System Active, not recruiting
Condition: Stress Disorders, Post-Traumatic Interventions: Diagnostic Test: CAPS-5; Diagnostic Test: PSSI-5; Diagnostic Test: CAPS-IV Sponsor: U.S. Army Medical Research and Development Command Recruiting
Condition: Diabetes Mellitus, Type 2 Intervention: Device: BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle Sponsor: Becton, Dickinson and Company Recruiting
Condition: Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy Intervention: Drug: Cenobamate Sponsor: SK Life Science, Inc. Enrolling by invitation
Condition: Diabetes Interventions: Device: BD Nano™ vs Nucleus; Device: NovoFine® vs Nucleus; Device: NovoTwist®/NovoFine® Plus vs Nucleus; Device: Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus Sponsor: Becton, Dickinson and Company Completed
Condition: Cancer Survivor Interventions: Procedure: Cognitive Assessment; Other: Questionnaire Administration Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI) Recruiting
Condition: Early Breast Cancer Intervention: Other: Endocrine therapy interruption Sponsors: International Breast Cancer Study Group; Alliance for Clinical Trials in Oncology; Canadian Cancer Trials Group; Breast International Group Recruiting
Condition: Leukemia Interventions: Drug: cytarabine; Drug: daunorubicin; Drug: midostaurin; Other: placebo; Drug: dexamethasone acetate Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Novartis Pharmaceuticals Active, not recruiting
Condition: Previously Treated Non-Small Cell Lung Cancer Intervention: Drug: Screening Platform Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conditions: Breast Cancer Stage 0; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III Interventions: Other: Usual Care; Other: Web-based decision aid Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Agency for Healthcare Research and Quality (AHRQ) Recruiting
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8; Elevated CA15-3 or CEA or CA27-29 Interventions: Other: Usual care disease monitoring; Other: Serum Tumor Marker directed disease monitoring; Other: Quality-of-Life Assessment; Other: Anxiety Questionnaire Administration Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conditions: Endometrial Undifferentiated Carcinoma; Endometrioid Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma; Stage IV Uterine Corpus Cancer AJCC v7; Stage IVA Uterine Corpus Cancer AJCC v7; Stage IVB Uterine Corpus Cancer AJCC v7 Interventions: Drug: Cediranib; Drug: Cediranib Maleate; Drug: Olaparib Sponsors: National Cancer Institute (NCI); NRG Oncology Active, not recruiting
Conditions: Cardiotoxicity; HER2/Neu Positive; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Carvedilol; Other: Laboratory Biomarker Analysis; Other: Patient Observation Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conditions: Invasive Breast Carcinoma; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer Intervention: Procedure: Biopsy of Breast Sponsors: NRG Oncology; National Cancer Institute (NCI) Suspended
Condition: Node Positive HER2 Negative Breast Cancer Interventions: Other: Placebo; Drug: Aspirin Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); United States Department of Defense; Bayer; Canadian Cancer Trials Group Recruiting
Conditions: Metastatic Malignant Neoplasm in Lymph Node; Metastatic Malignant Neoplasm in the Adrenal Gland; Metastatic Malignant Neoplasm in the Lung; Metastatic Malignant Neoplasm in the Pancreas; Metastatic Malignant Neoplasm in the Skin; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage II Renal Cell Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7; Unclassified Renal Cell Carcinoma Interventions: Procedure: Conventional Surgery; Biological: Nivolumab; Other: Patient Observation; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group Recruiting
Conditions: Recurrent Bladder Urothelial Carcinoma; Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7; Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7; Stage I Bladder Urothelial Carcinoma AJCC v6 and v7 Intervention: Drug: Atezolizumab Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group Active, not recruiting
Conditions: Cognitive Dysfunction; Memory Impairment Interventions: Drug: Donepezil 5 mg; Drug: Placebo Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI) Recruiting
Conditions: Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Drug: Crizotinib; Drug: Savolitinib; Drug: Sunitinib; Drug: Sunitinib Malate Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group Recruiting
Condition: Breast Carcinoma Interventions: Other: Health Education Program; Other: Weight Loss Intervention Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Division of Cancer Control; NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP); Canadian Cancer Trials Group Recruiting
Conditions: Metastatic Cutaneous Melanoma; Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Cutaneous Melanoma; Recurrent Non-Cutaneous Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage III Mucosal Melanoma of the Head and Neck AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7; Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7; Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7 Interventions: Biological: Ipilimumab; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Biological: Recombinant Interferon Alfa-2b Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Adenocarcinoma of the Gastroesophageal Junction; Gastric Adenocarcinoma; Gastric Cancer Interventions: Procedure: FDG-PET; Procedure: surgery; Drug: 5-FU; Drug: capecitabine; Drug: docetaxel; Drug: Irinotecan; Radiation: 3D-CRT; Radiation: IMRT Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Terminated
Conditions: Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Tamoxifen Citrate; Drug: Z-Endoxifen Hydrochloride Sponsor: National Cancer Institute (NCI) Active, not recruiting
Condition: Liposarcoma Intervention: Drug: efatutazone Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Daiichi Sankyo, Inc. Active, not recruiting
Condition: Colorectal Cancer Interventions: Biological: cetuximab; Drug: irinotecan hydrochloride; Drug: vemurafenib Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Roche-Genentech Active, not recruiting
Conditions: Breast Adenocarcinoma; HER2/Neu Negative; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Entinostat; Drug: Exemestane; Drug: Goserelin; Drug: Goserelin Acetate; Other: Placebo; Other: Quality-of-Life Assessment Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Breast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Atezolizumab; Drug: Paclitaxel; Biological: Pertuzumab; Other: Placebo; Other: Quality-of-Life Assessment; Biological: Trastuzumab Sponsors: National Cancer Institute (NCI); NRG Oncology Recruiting
Conditions: HER2/Neu Positive; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7 Interventions: Drug: Aromatase Inhibition Therapy; Drug: Carboplatin; Other: Cytology Specimen Collection Procedure; Drug: Docetaxel; Drug: Goserelin Acetate; Other: Laboratory Biomarker Analysis; Biological: Pertuzumab; Other: Quality-of-Life Assessment; Procedure: Therapeutic Conventional Surgery; Biological: Trastuzumab; Radiation: Whole Breast Irradiation Sponsors: National Cancer Institute (NCI); NRG Oncology Active, not recruiting
Conditions: Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma Interventions: Biological: Bevacizumab; Biological: Ipilimumab Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Stage II Breast Cancer; Stage IIIA Breast Cancer Interventions: Procedure: Axillary Lymph Node Dissection (ALND); Radiation: Nodal Radiation Therapy; Radiation: Axillary Radiation Therapy Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group Suspended
Conditions: Ann Arbor Stage III Grade 1 Follicular Lymphoma; Ann Arbor Stage III Grade 2 Follicular Lymphoma; Ann Arbor Stage III Grade 3 Follicular Lymphoma; Ann Arbor Stage IV Grade 1 Follicular Lymphoma; Ann Arbor Stage IV Grade 2 Follicular Lymphoma; Ann Arbor Stage IV Grade 3 Follicular Lymphoma; Grade 3a Follicular Lymphoma Interventions: Drug: Bendamustine Hydrochloride; Drug: Bortezomib; Radiation: Fludeoxyglucose F-18; Other: Laboratory Biomarker Analysis; Biological: Ofatumumab; Procedure: Positron Emission Tomography with Radiolabeled Targeting Agent Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Ann Arbor Stage II Diffuse Large B-Cell Lymphoma; Ann Arbor Stage III Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Lenalidomide; Drug: Prednisone; Biological: Rituximab; Drug: Vincristine Sulfate Sponsor: National Cancer Institute (NCI) Active, not recruiting
Condition: Colorectal Cancer Interventions: Drug: FOLFOX (chemotherapy); Other: 5 FUCMT (chemoradiation); Procedure: surgery; Procedure: magnetic resonance imaging or endorectal ultrasound Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group Active, not recruiting
Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer Interventions: Drug: Oxaliplatin; Drug: Leucovorin Calcium; Drug: Fluorouracil; Drug: Carboplatin; Drug: Paclitaxel; Procedure: Positron Emission Tomography; Procedure: Computed Tomography; Radiation: Radiation Therapy Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Active, not recruiting
Conditions: Ductal Breast Carcinoma In Situ; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma Interventions: Drug: Anastrozole; Drug: Exemestane; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Quality-of-Life Assessment; Drug: Systemic Chemotherapy; Drug: Tamoxifen Citrate Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Diarrhea; Gastrointestinal Complications; Unspecified Adult Solid Tumor, Protocol Specific Interventions: Drug: sulfasalazine; Other: placebo Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Completed
Conditions: Cancer Survivor; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders Intervention: Behavioral: Home-based sleep intervention Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Terminated
Condition: Inflammatory Breast Carcinoma Interventions: Drug: Olaparib; Radiation: Radiation Therapy Sponsor: National Cancer Institute (NCI) Recruiting
Conditions: Ann Arbor Stage II Non-Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Prednisone; Biological: Rituximab; Drug: Vincristine Sulfate; Drug: Vorinostat Sponsor: National Cancer Institute (NCI) Active, not recruiting
Condition: Glioblastoma Multiforme Interventions: Biological: bevacizumab; Drug: dasatinib; Other: placebo Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Completed
Condition: Ductal Breast Carcinoma In Situ Interventions: Other: Laboratory Biomarker Analysis; Biological: Trastuzumab; Radiation: Whole Breast Irradiation Sponsors: National Cancer Institute (NCI); NRG Oncology Active, not recruiting
Conditions: Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v6; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Biological: Bevacizumab; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Questionnaire Administration; Drug: Tamoxifen Citrate Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer Interventions: Biological: Bevacizumab; Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Drug: Paclitaxel; Other: Placebo Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; ECOG-ACRIN Cancer Research Group; North Central Cancer Treatment Group Active, not recruiting
Condition: Neoplasms, Breast Interventions: Drug: Lapatinib; Biological: Trastuzumab Sponsors: Novartis Pharmaceuticals; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; Canadian Cancer Trials Group Active, not recruiting
Conditions: Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer AJCC v6 and v7; Stage II Renal Cell Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7 Interventions: Other: Laboratory Biomarker Analysis; Other: Placebo; Other: Quality-of-Life Assessment; Drug: Sorafenib Tosylate; Drug: Sunitinib Malate Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; NCIC Clinical Trials Group; Southwest Oncology Group Completed
Conditions: Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIB Breast Cancer AJCC v7 Interventions: Drug: Anastrozole; Drug: Exemestane; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Drug: Tamoxifen Citrate Sponsors: National Cancer Institute (NCI); American College of Surgeons; Cancer and Leukemia Group B; NSABP Foundation Inc; NCIC Clinical Trials Group; North Central Cancer Treatment Group; Southwest Oncology Group Active, not recruiting
Condition: HER2+ Metastatic Breast Cancer (MBC) Interventions: Drug: neratinib; Drug: capecitabine; Drug: lapatinib Sponsor: Puma Biotechnology, Inc. Active, not recruiting
Condition: Breast Cancer Interventions: Drug: tamoxifen citrate; Procedure: adjuvant therapy; Radiation: radiation therapy Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; NCIC Clinical Trials Group; NRG Oncology Active, not recruiting
Conditions: Stage IB Breast Cancer; Stage II Breast Cancer Interventions: Radiation: regional nodal XRT; Radiation: chestwall XRT; Radiation: WBI Sponsors: NSABP Foundation Inc; National Cancer Institute (NCI); Radiation Therapy Oncology Group Recruiting
Condition: Prostate Cancer Interventions: Radiation: radiation therapy; Radiation: Whole-pelvic radiotherapy (WPRT) Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); NRG Oncology Active, not recruiting
Conditions: Borderline Ovarian Mucinous Tumor; Ovarian Mucinous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Stage IA Fallopian Tube Cancer AJCC v6 and v7; Stage IA Ovarian Cancer AJCC v6 and v7; Stage IB Fallopian Tube Cancer AJCC v6 and v7; Stage IB Ovarian Cancer AJCC v6 and v7; Stage IC Fallopian Tube Cancer AJCC v6 and v7; Stage IC Ovarian Cancer AJCC v6 and v7; Stage IIA Fallopian Tube Cancer AJCC v6 and v7; Stage IIA Ovarian Cancer AJCC V6 and v7; Stage IIB Fallopian Tube Cancer AJCC v6 and v7; Stage IIB Ovarian Cancer AJCC v6 and v7; Stage IIC Fallopian Tube Cancer AJCC v6 and v7; Stage IIC Ovarian Cancer AJCC v6 and v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7 Interventions: Biological: Bevacizumab; Drug: Capecitabine; Drug: Carboplatin; Other: Laboratory Biomarker Analysis; Drug: Oxaliplatin; Drug: Paclitaxel; Other: Quality-of-Life Assessment Sponsors: National Cancer Institute (NCI); NRG Oncology Active, not recruiting
Condition: Osteoarthritis Interventions: Drug: Celecoxib; Drug: Any commercially available NSAID with the indication for osteoarthritis Sponsor: Pfizer Completed
Conditions: Dyspnea; Fatigue; Nausea and Vomiting; Pain; Stage IV Breast Cancer Interventions: Radiation: Stereotactic Radiosurgery; Procedure: Therapeutic Conventional Surgery; Other: Laboratory Biomarker Analysis Sponsors: NRG Oncology; National Cancer Institute (NCI) Recruiting
Conditions: Diabetic Retinopathy; Diabetic Macular Edema Intervention: Sponsors: Jaeb Center for Health Research; National Eye Institute (NEI) Completed
Conditions: Central Nervous System Nongerminomatous Germ Cell Tumor; Childhood Central Nervous System Germinoma Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Drug: Carboplatin; Drug: Etoposide; Drug: Ifosfamide; Radiation: Intensity-Modulated Radiation Therapy Sponsors: Children's Oncology Group; National Cancer Institute (NCI) Active, not recruiting